GLP-1 Medications in the UAE

Scope Note for UAE Readers

This guide uses one table for two different categories: licensed prescription medicines and investigational research compounds. Ozempic, Wegovy, and Mounjaro are discussed as prescription products that require a licensed physician. Retatrutide is discussed only as an investigational compound for in-vitro laboratory research, with Remy-specific proof limited to batch documentation, COA verification, and supply-route transparency.

When a price or availability detail changes, we update the visible date and keep the research-use disclaimers intact rather than turning the article into medical advice or a treatment recommendation.

Above the fold: Ozempic price UAE lands at AED 744–1,200/month, Mounjaro price UAE at roughly AED 1,500–2,000/month, and Wegovy price UAE at AED 1,200–3,000/month depending on the 2.4mg titration step. Rybelsus and Saxenda sit at the lower end (AED ~800–1,100). Zepbound is Eli Lilly’s US brand name for the weight-loss indication of tirzepatide; UAE pharmacies dispense the same molecule under the Mounjaro name. Orforglipron has no confirmed UAE price and is not yet on pharmacy shelves. Every approved entry on the table requires a prescription from a DHA- or DOH-licensed physician.

What Are the Prescription Requirements in the UAE?

All GLP-1 receptor agonist medications—including Ozempic, Mounjaro, Wegovy, Rybelsus, and Saxenda—are classified as prescription-only drugs in the UAE. A valid prescription from a DHA- or DOH-licensed physician is required before any pharmacy can dispense these medications. The Dubai Health Authority has issued specific guidance against self-medication with GLP-1 compounds.

GLP-1 prescriptions are available through major UAE pharmacy chains, including BinSina Pharmacy, Aster Pharmacy, and Life Pharmacy. Some pharmacies offer online ordering and delivery services, but a valid prescription must be presented or uploaded before dispensing.

Clinics offering GLP-1 consultation and prescription in the UAE include:

• Zone.Health — specialist GLP-1 weight management clinic in Dubai
• Euromed Clinic — medical weight loss programs with GLP-1 therapy
• Emirates Hospitals — endocrinology and metabolic health departments
• Endocare Clinic — dedicated endocrinology and diabetes center

Purchasing GLP-1 medications without a valid prescription is illegal under UAE pharmaceutical regulations. The DHA has issued public warnings against self-medication with weight loss injectables, citing risks of dosing errors, contraindication conflicts, and counterfeit products in unregulated channels. For a side-by-side tolerability comparison of these medications, see our Ozempic vs Mounjaro vs Wegovy side effects review.

Why Is There an Insurance Coverage Gap?

UAE medical insurance companies generally do not cover GLP-1 receptor agonist prescriptions when prescribed for weight loss or obesity management. This exclusion applies to Ozempic, Wegovy, Mounjaro, Saxenda, and Rybelsus when the primary indication is weight reduction rather than type 2 diabetes management.

When GLP-1 medications are prescribed specifically for type 2 diabetes, partial insurance coverage may be available depending on the individual policy and insurance provider. However, coverage for the diabetes indication varies significantly between insurers and plan tiers, and pre-authorization is typically required.

This coverage gap creates a substantial out-of-pocket cost of AED 744–1,734 per month for most patients seeking GLP-1 therapy for weight management. At current pricing, annual treatment costs range from approximately AED 8,900 to AED 20,800—a significant financial barrier for many residents. For detailed Wegovy pricing and dosing schedules in the UAE market, see our Wegovy price and dosing guide.

Despite these costs, demand is surging. The UAE GLP-1 receptor agonist market is projected to reach USD 371.6 million by 2030, driven by rising obesity prevalence and growing awareness of these therapies. The gap between clinical demand and insurance coverage remains one of the defining dynamics of the UAE weight management landscape. Our Ozempic alternatives in Dubai article breaks down cost-per-receptor across available compounds.

For a data-first read on the epidemiology behind that demand, see our UAE obesity statistics and GLP-1 landscape analysis. If the search shifts from UAE pharmacy access into wider country routing across Saudi Arabia, Qatar, or Lebanon, use the UAE, GCC and Lebanon guide hub.

What Does the UAE Obesity Landscape Look Like?

The UAE has one of the highest obesity rates globally, creating significant demand for effective pharmacological interventions. A 2025 cross-sectional study of over 440,000 adults in Dubai found that 63% of the adult population is overweight or obese, with 28% classified as obese by BMI criteria.

The diabetes burden is equally significant. The UAE has a 19.3% diabetes prevalence—among the highest rates worldwide—and this figure is projected to continue rising. UAE nationals have a higher prevalence of overweight and obesity (68.3%) compared to expatriate populations, reflecting both genetic predisposition and lifestyle factors in the region. GLP-1 usage is also growing among non-diabetic populations, a trend with its own body of clinical evidence.

These epidemiological realities have positioned the UAE as the fastest-growing GLP-1 market in the Middle East and Africa region. The convergence of high obesity prevalence, high disposable income, medical tourism infrastructure, and limited insurance coverage creates a unique market dynamic where out-of-pocket spending on GLP-1 therapies is substantial and growing.

Orforglipron in the UAE — Oral GLP-1 Pipeline Status

Orforglipron is Eli Lilly’s oral, non-peptide GLP-1 receptor agonist — the first small-molecule entry to the class and the first credible needle-free alternative to weekly injections. Because it is taken by mouth rather than injected, it does not require refrigeration, which is a meaningful logistics shift for UAE distribution if it lands. As of April 2026 it is under FDA review and not yet registered with MoHAP, DHA, or DOH; it cannot be legally dispensed by any UAE pharmacy.

Orforglipron UAE price: no confirmed AED price yet

Orforglipron is not yet on UAE shelves and the Emirates Drug Establishment (EDE) has not issued a reference price. Once MoHAP registration completes, the AED price will fall under the federal reference-pricing framework EDE administers — benchmarked against the lowest-priced reference market, with a 15% agent margin and a 20–28% pharmacy margin cap. Insurance treatment will likely mirror the existing GLP-1 pattern: covered for the diabetes indication, generally excluded for weight management. Until registration completes, no DHA- or DOH-licensed physician can write a UAE prescription for orforglipron, and no pharmacy chain (BinSina, Aster, Life) can stock it.

For the regulatory timeline, see is orforglipron approved. For Eli Lilly’s commercial brand framing, see Foundayo (orforglipron) FDA approval status.

How GLP-1 Weight Loss Injections Work

Mechanism

GLP-1 receptor agonists mimic the gut hormone glucagon-like peptide-1. They slow gastric emptying, blunt post-meal glucose spikes, and signal satiety in the hypothalamus—so calorie intake drops without willpower doing the heavy lifting. Subcutaneous dosing keeps blood levels steady, which is why weekly weight loss injections like Ozempic and Mounjaro outperform older oral options on adherence and effect size. For dosing, titration, and trial data on the GIP/GLP-1 dual agonist, see our Mounjaro (tirzepatide) injection guide.

Trial-Average Weight Loss

Ozempic: 10–15% over 68 weeks at 2.0mg. Wegovy: 14.9% in STEP 1 at 2.4mg. Mounjaro: 20–25% across the SURMOUNT series. Saxenda: ~6% over 56 weeks at 3mg. For a side-by-side, see the weight loss injections comparison guide.

Dosing & Eligibility in the UAE

Starting Doses & Titration

All weekly GLP-1s start low and step up to limit GI side effects. Ozempic begins at 0.25mg/week for four weeks, then 0.5mg, with maintenance at 1.0–2.0mg depending on response. Wegovy follows a 5-step titration over 16 weeks to a 2.4mg maintenance dose. Mounjaro starts at 2.5mg/week and titrates to 5–15mg.

Eligibility Thresholds

Trial-aligned eligibility is BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, OSA). UAE prescribing decisions are made by a DHA- or DOH-licensed physician—this article is reference, not advice.

Blood Sugar & Metabolic Effects

Blood Sugar & Insulin Sensitivity

Glucose improvements typically appear within the first 4–8 weeks—before substantial weight loss. In type 2 diabetes trials, Ozempic and Mounjaro both produce HbA1c reductions of 1.0–1.8%, putting them among the most effective glucose-lowering agents on the UAE market.

Lipids, Liver, Blood Pressure

Beyond glucose, GLP-1 trials report lower LDL, reduced liver fat, and modest blood-pressure drops. These effects often track ahead of what weight loss alone would predict, suggesting direct receptor-driven mechanisms—a useful detail for protocol design in metabolic research.

Side Effects in the Titration Window

Common GI Effects

Nausea, vomiting, diarrhoea, and constipation are the dominant adverse events. They’re dose-dependent and concentrate in the first month after each step-up. Trial data: roughly 30–50% of patients report at least one GI symptom in month one, with incidence falling sharply by month three.

If Symptoms Persist

Persistent symptoms usually resolve with a slower titration, a temporary dose hold, or switching molecule. UAE prescribers manage this directly; the data above is published trial behaviour, not a prescribing recommendation.

What the Trials Pair the Drug With

Every Phase 3 weight-loss trial pairs the drug with a reduced-calorie diet and ~150 minutes/week of physical activity. That pairing is part of the published efficacy number, not a separate add-on—when researchers reference “14.9% on Wegovy” or “22.5% on Mounjaro”, that’s the combined intervention, not the drug in isolation. The data above is published trial behaviour; UAE prescribing decisions sit with DHA- or DOH-licensed clinicians.

UAE Treatments Beyond GLP-1

IV Drips, Gastric Balloons, Other Devices

Dubai wellness clinics market IV drips (lipotropic, B-complex, amino acids), gastric balloons, cryolipolysis, and meal-replacement programmes alongside the injectables. Evidence quality varies—most trial-grade weight-loss data still sits with the GLP-1 class, the dual GIP/GLP-1 class, and the new triple agonists.

Research-Grade Retatrutide

For laboratory use in the UAE, Remy Peptides supplies HPLC-verified retatrutide for in-vitro research peptides UAE programmes, with batch documentation in our Janoshik COA library. Comparison reads: Retatrutide vs Orforglipron for the triple-agonist vs oral GLP-1 contrast, and Retatrutide vs Tirzepatide vs CagriSema for the multi-receptor comparison.

What Is Not Available Yet in the UAE?

Several entries in the GLP-1 cluster are not yet on UAE shelves and shouldn’t be promised by any pharmacy or clinic. Mapping what is and isn’t legally dispensable removes the most common sources of confusion in this category.

Orforglipron UAE availability

Eli Lilly’s oral, non-peptide GLP-1 is still under FDA review (April 2026). It is not registered with MoHAP, not listed on the DHA or DOH formularies, and has no confirmed AED price. No UAE pharmacy can legally dispense it yet. See is orforglipron approved for the timeline.

Foundayo

Foundayo is Eli Lilly’s commercial brand name for orforglipron in some markets. The brand has not been registered or launched in the UAE; UAE searches for “Foundayo” should be read as orforglipron pending status. Background: Foundayo / orforglipron FDA approval status.

Zepbound naming

Zepbound is Eli Lilly’s US brand for tirzepatide on the weight-loss indication. It is not a UAE pharmacy SKU and is not separately approved by DHA. UAE-licensed tirzepatide is dispensed under the Mounjaro name, regardless of whether the prescription is written for diabetes or weight management.

Retatrutide

Eli Lilly’s GLP-1/GIP/GCGR triple agonist remains investigational and is not approved by FDA, EMA, or MoHAP for human use anywhere. In the UAE it exists only as in-vitro research material with batch documentation; it is not a prescription product and cannot be dispensed by any pharmacy. See the scope note above for how this article handles approved versus research-use entries.